Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.

Hood SP, Foulds GA, Imrie H, Reeder S, McArdle SEB, Khan M, Pockley AG.

Front Immunol. 2019 Jan 25;9:3169. doi: 10.3389/fimmu.2018.03169. eCollection 2018.

2.

Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer.

Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, Nagarajan D, Reeder S, Johnson C, Hood S, Moseley PM, Chan SYT, Pockley AG, Rutella S, McArdle SEB.

Front Immunol. 2018 Sep 11;9:2028. doi: 10.3389/fimmu.2018.02028. eCollection 2018.

3.

Immune Landscape of Breast Cancers.

Nagarajan D, McArdle SEB.

Biomedicines. 2018 Feb 11;6(1). pii: E20. doi: 10.3390/biomedicines6010020. Review.

4.

Identifying the Presence of Prostate Cancer in Individuals with PSA Levels <20‚ÄČng ml-1 Using Computational Data Extraction Analysis of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.

Cosma G, McArdle SE, Reeder S, Foulds GA, Hood S, Khan M, Pockley AG.

Front Immunol. 2017 Dec 18;8:1771. doi: 10.3389/fimmu.2017.01771. eCollection 2017.

5.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Clin Cancer Res. 2016 Feb 15;22(4):905-14. doi: 10.1158/1078-0432.CCR-15-0610. Epub 2015 Aug 3.

6.

Prostate cancer: Important steps and considerations in the design of therapeutic vaccines.

McArdle SE, Pockley AG, Gibson GR, Rees RC.

Oncoimmunology. 2014 Feb 14;3:e28049. eCollection 2014.

7.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

Abdel-Fatah TM, McArdle SE, Johnson C, Moseley PM, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Br J Cancer. 2014 May 13;110(10):2450-61. doi: 10.1038/bjc.2014.168. Epub 2014 Apr 22.

8.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.

Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE.

Eur J Immunol. 2014 Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7.

9.

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC.

Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8.

PMID:
23225347
10.

The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo.

Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T.

J Biol Chem. 2012 Apr 20;287(17):13633-43. doi: 10.1074/jbc.M111.308973. Epub 2012 Mar 5.

11.

Cancer/testis antigens for therapeutic use.

Mathieu MG, Miles AK, Li G, McArdle SE, Rees RC.

J BUON. 2009 Sep;14 Suppl 1:S97-102. Review.

12.

HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers.

Mathieu MG, Linley AJ, Reeder SP, Badoual C, Tartour E, Rees RC, McArdle SE.

Cancer Immun. 2010 Jan 11;10:2.

13.

Tumor immunology: new perspectives.

McArdle SE, Rees RC.

Cancer Res. 2009 Sep 15;69(18):7157-9. doi: 10.1158/0008-5472.CAN-09-0631. Epub 2009 Sep 8.

14.

Estimation of peptide concentration by a modified bicinchoninic acid assay.

Kapoor KN, Barry DT, Rees RC, Dodi IA, McArdle SE, Creaser CS, Bonner PL.

Anal Biochem. 2009 Oct 1;393(1):138-40. doi: 10.1016/j.ab.2009.06.016. Epub 2009 Jun 17.

PMID:
19539599
15.

CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model.

Ali SA, Rezvan H, McArdle SE, Khodadadi A, Asteal FA, Rees RC.

Parasite Immunol. 2009 Jul;31(7):373-83. doi: 10.1111/j.1365-3024.2009.01111.x.

16.

Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?

Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees RC.

Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. doi: 10.1007/s00262-009-0675-x. Epub 2009 Mar 4. Review.

PMID:
19259670
17.
18.

Identification of immunogenic MHC class II Tyrosinase-derived peptides using HLA-DR1 and HLA-DR4 transgenic mice.

Horton RB, Laversin SA, Reeder SP, Rees RC, McArdle SE.

Protein Pept Lett. 2007;14(5):455-60.

PMID:
17584170
19.

HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides.

Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D, Lemonnier FA, Straten PT, Mueller L, Rees RC, McArdle SE.

Cancer Immunol Immunother. 2007 Dec;56(12):1885-95. Epub 2007 May 9.

PMID:
17487488
20.

Identification of a novel prostate cancer-associated tumor antigen.

Miles AK, Rogers A, Li G, Seth R, Powe D, McArdle SE, McCulloch TA, Bishop MC, Rees RC.

Prostate. 2007 Feb 15;67(3):274-87.

PMID:
17192878
21.

The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines.

Assudani DP, Horton RB, Mathieu MG, McArdle SE, Rees RC.

Cancer Immunol Immunother. 2007 Jan;56(1):70-80. Epub 2006 Mar 23. Review.

PMID:
16555057
22.

Immunity to tumour antigens.

Li G, Ali SA, McArdle SE, Mian S, Ahmad M, Miles A, Rees RC.

Curr Pharm Des. 2005;11(27):3501-9. Review.

PMID:
16248804
23.
24.

Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53.

Rojas JM, McArdle SE, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC.

Cancer Immunol Immunother. 2005 Mar;54(3):243-53. Epub 2004 Sep 21.

PMID:
15449037
25.

Anti-tumour therapeutic efficacy of OX40L in murine tumour model.

Ali SA, Ahmad M, Lynam J, McLean CS, Entwisle C, Loudon P, Choolun E, McArdle SE, Li G, Mian S, Rees RC.

Vaccine. 2004 Sep 9;22(27-28):3585-94.

PMID:
15315837
26.

Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.

Parkinson RJ, Mian S, Bishop MC, Gray T, Li G, McArdle SE, Ali S, Rees RC.

Prostate. 2003 Jun 15;56(1):65-73.

PMID:
12746848
27.

Phenotypic and functional differences of dendritic cells generated under different in vitro conditions.

McArdle SE, Ali SA, Li G, Mian S, Rees RC.

Methods Mol Med. 2003;81:359-75. No abstract available.

PMID:
12725131
29.

Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.

McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK.

Cancer Immunol Immunother. 2000 Oct;49(8):417-25.

PMID:
11043848

Supplemental Content

Loading ...
Support Center